Zeria Pharmaceutical Co., Ltd. Share Price

Equities

4559

JP3428850006

Pharmaceuticals

Market Closed - Japan Exchange 11:30:00 26/04/2024 am IST 5-day change 1st Jan Change
2,059 JPY +0.54% Intraday chart for Zeria Pharmaceutical Co., Ltd. +2.29% +2.08%

Financials

Sales 2024 * 75B 474M 39.49B Sales 2025 * 79.9B 505M 42.07B Capitalization 90.76B 574M 47.79B
Net income 2024 * 8.25B 52.16M 4.34B Net income 2025 * 8.3B 52.48M 4.37B EV / Sales 2024 * 1.57 x
Net Debt 2024 * 27.16B 172M 14.3B Net Debt 2025 * 21.93B 139M 11.55B EV / Sales 2025 * 1.41 x
P/E ratio 2024 *
11 x
P/E ratio 2025 *
10.9 x
Employees 1,729
Yield 2024 *
2.19%
Yield 2025 *
2.33%
Free-Float 55.7%
More Fundamentals * Assessed data
Dynamic Chart
Borsch Med Pte. Ltd. Introduces Chondroitin Supplements of Zeria Pharmaceutical Co. Ltd to Singapore for Healthy Joints CI
Zeria Pharmaceutical's Profit Up 41% in Fiscal Q1-Q3 MT
Japanese Shares End Firmer on Friday on BoJ Policy Outlook MT
Zeria Pharmaceutical Books Higher Fiscal H1 Attributable Profit on Loss Provision Reversal MT
Zeria Pharmaceutical Co., Ltd. Announces Dividend for the Second Quarter of Fiscal Year Ending March 31, 2024, Payable on December 1, 2023 CI
Zeria Pharmaceutical Co., Ltd. Provides Dividend Guidance for the Year Ending March 31, 2024 CI
Zeria Pharmaceutical’s Attributable Profit Up 12.1% in Fiscal Q1 on Absence of Forex Losses MT
Zeria Pharmaceutical Co., Ltd. Provides Dividend Forecast for the Fiscal Year Ending March 31, 2024 CI
Zeria Pharmaceutical Co., Ltd. Provides Consolidated Financial Forecast for the Six Months of 2024 and the Fiscal Year Ending March 31, 2024 CI
Zeria Pharmaceutical Co., Ltd. Provides Dividend Forecast for the Second Quarter of 2024 CI
Tranche Update on Zeria Pharmaceutical Co., Ltd.'s Equity Buyback Plan announced on May 11, 2022. CI
Zeria Pharmaceutical Co., Ltd.'s Equity Buyback announced on May 11, 2022, has closed with 263,900 shares, representing 0.6% for ¥545.29 million. CI
Zeria Pharmaceutical Co., Ltd. Provides Year End Dividend Guidance for the Full Year Ending March 31, 2024 CI
Zeria Pharmaceutical Co., Ltd. Announces Year End Dividend for the Full Year Ending March 31, 2023, Payable on June 30, 2023; Provides Second Quarter Dividend Guidance for the Full Year Ending March 31, 2024 CI
Zeria Pharmaceutical Co., Ltd. Provides Consolidated Earnings Guidance for the First Six Months and Full Year Ending March 31, 2024 CI
More news
1 day+0.54%
1 week+2.29%
Current month-3.42%
1 month-5.51%
3 months+1.53%
6 months+2.39%
Current year+2.08%
More quotes
1 week
2 033.00
Extreme 2033
2 072.00
1 month
1 996.00
Extreme 1996
2 156.00
Current year
1 995.00
Extreme 1995
2 270.00
1 year
1 880.00
Extreme 1880
2 600.00
3 years
1 837.00
Extreme 1837
2 600.00
5 years
1 471.00
Extreme 1471
2 600.00
10 years
1 281.00
Extreme 1281
2 677.00
More quotes
Managers TitleAgeSince
Chief Executive Officer 83 01/72/01
President 52 01/10/01
Chief Tech/Sci/R&D Officer 66 01/85/01
Members of the board TitleAgeSince
Chief Executive Officer 83 01/72/01
Director/Board Member 76 01/06/01
Chief Tech/Sci/R&D Officer 66 01/85/01
More insiders
Date Price Change Volume
26/24/26 2,059 +0.54% 31,400
25/24/25 2,048 -0.73% 43,500
24/24/24 2,063 +0.29% 26,900
23/24/23 2,057 -0.05% 17,900
22/24/22 2,058 +2.24% 32,800

Delayed Quote Japan Exchange, April 26, 2024 at 11:30 am IST

More quotes
Zeria Pharmaceutical Co Ltd is a Japan-based company mainly engaged in the development of ethical drug business, consumer healthcare business and other business. The Company operates in two business segments. The Ethical Drug segment is engaged in the research, development, manufacture and sale of ethical drugs. The Consumer Healthcare segment is engaged in the manufacture, purchase and sale of over-the-counter (OTC) drugs, health foods, quasi drugs and cosmetics related to self-medication. The others include insurance agency business and real estate business, as well as various maintenance business such as purchasing and sale of promotional materials.
Calendar
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
More Ratings
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
1
Last Close Price
2,059 JPY
Average target price
2,810 JPY
Spread / Average Target
+36.47%
Consensus